Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IMS Health’s Yan Shangjun On China’s Changing Diabetes Market: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

IMS Health Inc. Pharma Insight Principal Yan Shangjun sits down with PharmAsia News to talk about the evolution of China’s diabetes market and how opinions of Chinese doctors affect the market.


Related Content

Avandia Re-Adjudication Might Result In “Refreshing” Restricted Distribution Roll Back
J&J Gains FDA OK For First-In-Class Type 2 Diabetes Drug Invokana
Bristol Signals Dapaglifozin’s Back On Track, Plans FDA Resubmission


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts